Abstract: Neural Normalized MinSum (N-NMS) decoding for improving frame error rate (FER) performance on linear block codes over conventional normalized MinSum (NMS). Dynamic multiplicative weights are assigned to each check-to-variable message in each iteration to efficiently provide training parameters of N-NMS that support N-NMS for longer block lengths. Embodiment are described for neural two-dimensional normalized MinSum (N-2D-NMS) decoders requiring fewer training parameters. The N-2D-NMS approaches for example use the same weight for edges with the same check and/or variable node degree. Simulation results indicate that that this LDPC decoding performs similarly to previous techniques while substantially reducing the amount of training necessary.

Abstract: Provided herein are compositions, systems, and methods for modifying a human APOC3 gene, PCSK9 gene, or ANGPTL3 gene. Systems, compositions, and methods may comprise a CRISPR-associated (Cas) protein or uses thereof. Systems, compositions, and methods of the present disclosure may be useful for treatment of APOC3 associated conditions, including familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG).

Abstract: A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second polymer includes an alginate. The second coating has a hemostatic agent dispersed in the second polymer such that the second polymer releases the hemostatic agent as the second polymer degrades. The hemostatic agent is selected from epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. In some embodiments, systems and methods are disclosed.

Abstract: Provided herein, in certain embodiments, are programmable nucleases, guide nucleic acids, and complexes thereof. Certain programmable nucleases provided herein comprise a RuvC domain. Also provided herein are nucleic acids encoding said programmable nucleases and guide nucleic acids. Also provided herein are methods of genome editing, methods of regulating gene expression, and methods of detecting nucleic acids with said programmable nucleases and guide nucleic acids.

Abstract: A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating includes a polymer, collagen, glycerin and a hemostatic agent. The polymer is selected from the group of polyhydroxybutyrate, polyglycerol sebacate and adducts of polyglycerol sebacate. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

Abstract: A surgical device configured to surround an implantable medical device that includes a collagen membrane and a coating embedded in the membrane, the coating including at least one active pharmaceutical ingredient.

Abstract: A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating including collagen, glycerin and a hemostatic agent. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

Abstract: Provided herein are viral vectors comprising a transgene encoding a compact effector protein and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Due to the small nature of the effector protein, the viral vector has ample room for additional genome editing cargo, such as a guide nucleic acid and a donor nucleic acid. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are substituted imidazo[1,2-a]pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a Janus kinase-mediated disease.

Abstract: Neural Normalized MinSum (N-NMS) decoding for improving frame error rate (FER) performance on linear block codes over conventional normalized MinSum (NMS). Dynamic multiplicative weights are assigned to each check-to-variable message in each iteration to efficiently provide training parameters of N-NMS that support N-NMS for longer block lengths. Embodiment are described for neural two-dimensional normalized MinSum (N-2D-NMS) decoders requiring fewer training parameters. The N-2D-NMS approaches for example use the same weight for edges with the same check and/or variable node degree. Simulation results indicate that that this LDPC decoding performs similarly to previous techniques while substantially reducing the amount of training necessary.

Abstract: Provided herein, in certain embodiments, are programmable nucleases, guide nucleic acids, and complexes thereof. Certain programmable nucleases provided herein comprise a RuvC domain. Also provided herein are nucleic acids encoding said programmable nucleases and guide nucleic acids. Also provided herein are methods of genome editing, methods of regulating gene expression, and methods of detecting nucleic acids with said programmable nucleases and guide nucleic acids.

Abstract: A method of forming an implant includes positioning a first mesh component of the implant within a second mesh component of the implant to form an implant assembly. The implant assembly is manipulated to join the first mesh component with the second mesh component.

Abstract: Provided herein, in certain embodiments, are programmable nucleases, guide nucleic acids, and complexes thereof. Certain programmable nucleases provided herein comprise a RuvC domain. Also provided herein are nucleic acids encoding said programmable nucleases and guide nucleic acids. Also provided herein are methods of genome editing, methods of regulating gene expression, and methods of detecting nucleic acids with said programmable nucleases and guide nucleic acids.

Abstract: A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second coating has ellagic acid dispersed in the second polymer such that the second polymer releases the ellagic acid as the second polymer degrades. In some embodiments, systems and methods are disclosed.

Abstract: A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second polymer includes an alginate. The second coating has a hemostatic agent dispersed in the second polymer such that the second polymer releases the hemostatic agent as the second polymer degrades. The hemostatic agent is selected from epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. In some embodiments, systems and methods are disclosed.

Abstract: A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating includes a polymer, collagen, glycerin and a hemostatic agent. The polymer is selected from the group of polyhydroxybutyrate, polyglycerol sebacate and adducts of polyglycerol sebacate. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

Abstract: A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating including collagen, glycerin and a hemostatic agent. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

Abstract: A surgical device configured to surround an implantable medical device that includes a collagen membrane and a coating embedded in the membrane The coating including at least one active pharmaceutical ingredient.

Abstract: A package for a surgical implant includes a body having a side wall including opposite top and bottom ends. The body includes a bottom wall coupled to the bottom end. The body includes a flange extending outwardly from the top end. Inner surfaces of the walls define a cavity. The top end defines an opening that is in communication with the cavity. An insert extends from the bottom wall such that the insert is positioned in the cavity. A lid is configured to be coupled to the flange such that the lid covers the opening. Devices, kits and systems are disclosed.

Abstract: A surgical instrument includes a body extending along a longitudinal axis between opposite proximal and distal end surfaces. The distal end surface includes a first cavity and a second cavity. The first cavity includes a first light bulb disposed therein. The second cavity includes a second light bulb disposed therein. A shaft includes opposite proximal and distal ends. The proximal end is coupled to the body. A blade is coupled to the distal end. The first light bulb is an ultraviolet (UV) light bulb and the second light bulb is configured to emit visible light. Systems and methods of use are disclosed.